Payment overview · 2025
General Payments
$814.04
45 reported records · 11 companies
Healthcare provider profile · identity verified
Brian Francis, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTH WILLIAMSON, KY · NPI 1780663971
Verified facts
What the public records show
CMS Open Payments records show Brian Francis, M.D. received $814.04 in general payments during 2025 across 45 reported records.
Novo Nordisk Inc accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $236.92 | 29.1% | 15 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $225.04 | 27.6% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $92.13 | 11.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.51 | 6.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.20 | 6.4% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $39.11 | 4.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.08 | 3.6% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $23.33 | 2.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.28 | 2.9% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $19.60 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.84 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $814.04 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $225.04 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $215.62 | 14 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $92.13 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $80.78 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $55.51 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $55.51 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.20 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 180 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
68 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
107 | 27 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
180 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1562 | 182 |
| Gabapentin | Gabapentin | 1131 | 159 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 793 | 189 |
| Levothyroxine Sodium | Levothyroxine Sodium | 679 | 151 |
| Alprazolam | Alprazolam | 646 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 644 | 161 |
| Omeprazole | Omeprazole | 635 | 139 |
| Clonazepam | Clonazepam | 519 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 476 | 104 |
| Lisinopril | Lisinopril | 446 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 417 | 106 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 365 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 340 | 91 |
| Ibuprofen | Ibuprofen | 309 | 88 |
| Pregabalin | Pregabalin | 308 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 308 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 280 | 62 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 273 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 270 | 34 |
| Glimepiride | Glimepiride | 264 | 64 |
| Prednisone | Prednisone | 258 | 148 |
| Tizanidine Hcl | Tizanidine Hcl | 256 | 58 |
| Potassium Chloride | Potassium Chloride | 251 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 248 | 98 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 248 | 61 |
| Simvastatin | Simvastatin | 242 | 64 |
| Tramadol Hcl | Tramadol Hcl | 241 | 62 |
| Mirtazapine | Mirtazapine | 239 | 47 |
| Montelukast Sodium | Montelukast Sodium | 235 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 60 |
| Diazepam | Diazepam | 221 | 34 |
| Sertraline Hcl | Sertraline Hcl | 220 | 47 |
| Trazodone Hcl | Trazodone Hcl | 216 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 59 |
| Carvedilol | Carvedilol | 212 | 52 |
| Ondansetron Hcl | Ondansetron Hcl | 210 | 75 |
| Metformin Hcl Er | Metformin Hcl | 202 | 54 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 191 | 44 |
| Losartan Potassium | Losartan Potassium | 188 | 50 |
| Torsemide | Torsemide | 185 | 48 |
| Ozempic | Semaglutide | 180 | 40 |
| Mounjaro | Tirzepatide | 167 | 24 |
| Famotidine | Famotidine | 154 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 38 |
| Furosemide | Furosemide | 152 | 38 |
| Buspirone Hcl | Buspirone Hcl | 151 | 36 |
| Jardiance | Empagliflozin | 151 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 35 |
| Celecoxib | Celecoxib | 142 | 37 |
| Irbesartan | Irbesartan | 142 | 29 |
| Tradjenta | Linagliptin | 137 | 32 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 136 | 17 |
| Allopurinol | Allopurinol | 135 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 135 | 30 |
| Bupropion Xl | Bupropion Hcl | 134 | 35 |
| Methocarbamol | Methocarbamol | 129 | 39 |
| Lorazepam | Lorazepam | 128 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 127 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 123 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 121 | 87 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 121 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 37 |
| Amoxicillin | Amoxicillin | 115 | 91 |
| Azithromycin | Azithromycin | 113 | 72 |
| Metformin Hcl | Metformin Hcl | 108 | 31 |
| Synthroid | Levothyroxine Sodium | 107 | 27 |
| Cefdinir | Cefdinir | 105 | 85 |
| Meloxicam | Meloxicam | 104 | 33 |
| Testosterone Cypionate | Testosterone Cypionate | 100 | 20 |
| Fenofibrate | Fenofibrate | 99 | 21 |
| Promethazine Hcl | Promethazine Hcl | 96 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 93 | 46 |
| Donepezil Hcl | Donepezil Hcl | 92 | 20 |
| Atenolol | Atenolol | 91 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 24 |
| Xarelto | Rivaroxaban | 87 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 84 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 82 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 81 | 61 |
| Dexlansoprazole Dr | Dexlansoprazole | 80 | 13 |
| Eliquis | Apixaban | 78 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 17 |
| Levetiracetam | Levetiracetam | 72 | suppressed |
| Chlorthalidone | Chlorthalidone | 71 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 69 | 47 |
| Linzess | Linaclotide | 68 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 68 | 19 |
| Fluconazole | Fluconazole | 67 | 36 |
| Nebivolol Hcl | Nebivolol Hcl | 67 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 66 | 17 |
| Lansoprazole | Lansoprazole | 64 | 16 |
| Levofloxacin | Levofloxacin | 64 | 55 |
| Ezetimibe | Ezetimibe | 63 | 13 |
| Farxiga | Dapagliflozin Propanediol | 63 | 15 |
| Nabumetone | Nabumetone | 63 | 18 |
| Sucralfate | Sucralfate | 63 | 17 |
| Aripiprazole | Aripiprazole | 62 | 16 |
| Vascepa | Icosapent Ethyl | 62 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 44 |
| Ibu | Ibuprofen | 61 | 23 |
| Cephalexin | Cephalexin | 60 | 40 |
| Sumatriptan Succinate | Sumatriptan Succinate | 60 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 58 | 16 |
| Meclizine Hcl | Meclizine Hcl | 57 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 17 |
| Finasteride | Finasteride | 52 | 16 |
| Spironolactone | Spironolactone | 52 | 13 |
| Januvia | Sitagliptin Phosphate | 50 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 11 |
| Benazepril Hcl | Benazepril Hcl | 45 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 45 | 18 |
| Naproxen | Naproxen | 45 | 14 |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | 11 |
| Movantik | Naloxegol Oxalate | 44 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | 12 |
| Azelastine Hcl | Azelastine Hcl | 41 | 19 |
| Estradiol | Estradiol | 41 | suppressed |
| Rybelsus | Semaglutide | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 40 | 13 |
| Felodipine Er | Felodipine | 39 | 11 |
| Methylprednisolone | Methylprednisolone | 39 | 34 |
| Theophylline Er | Theophylline Anhydrous | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 36 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 36 | 14 |
| Hydrocortisone | Hydrocortisone | 35 | 11 |
| Invokana | Canagliflozin | 35 | suppressed |
| Mupirocin | Mupirocin | 35 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 15 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 33 | 14 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 29 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 28 | suppressed |
| Nystatin | Nystatin | 28 | 13 |
| Ondansetron Odt | Ondansetron | 28 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 26 |
| Trulance | Plecanatide | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Modafinil | Modafinil | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 11 |
| Zaleplon | Zaleplon | 24 | suppressed |
| Belsomra | Suvorexant | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 15 |
| Glipizide | Glipizide | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 11 |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Corlanor | Ivabradine Hcl | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $814.04 · 45 records | Novo Nordisk Inc | Auvelity, BREZTRI, EVENITY, FREESTYLE LIBRE 2, Fluad, Flucelvax, Kerendia, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VIVITROL, Wegovy, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error